Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes
| Autor: | Prajakti A. Kothare, A. de la Peña, Helle Linnebjerg, C. S. Ernest, M E Trautmann, M. Atkins, Z. Skrivanek |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Injections Subcutaneous Incretin Type 2 diabetes Placebo Drug Administration Schedule Endocrinology Internal medicine Diabetes mellitus Internal Medicine medicine Humans Hypoglycemic Agents Insulin Cross-Over Studies business.industry Venoms digestive oral and skin physiology Middle Aged medicine.disease Postprandial Period Crossover study Postprandial Diabetes Mellitus Type 2 Area Under Curve Exenatide Female business Peptides medicine.drug |
| Zdroj: | Diabetic medicine : a journal of the British Diabetic Association. 23(3) |
| ISSN: | 0742-3071 |
| Popis: | Aims Exenatide is an incretin mimetic whose effect on glycaemic control in patients with Type 2 diabetes is currently under investigation. This study assessed the effect of injection time relative to a standardized meal on postprandial pharmacodynamics of exenatide in patients with Type 2 diabetes. Methods Eighteen patients participated in this single-centre, open-label, placebo-controlled, randomized, six-way crossover study. Patients received subcutaneous injections of either placebo (−15 min) or 10 µg of exenatide at −60, −15, 0, +30 or +60 min relative to a standardized breakfast meal on six consecutive days. Serial blood samples were assayed for plasma glucose and insulin concentrations. Results For all exenatide treatments, incremental postprandial glucose area under the postprandial plasma glucose curve from zero to 6 h (AUC0−6 h) was significantly reduced compared with placebo. When exenatide was administered before (−60, −15 min) or with the meal (0 min), peak postprandial glucose concentrations were significantly decreased (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text